Multiple Myeloma Conversations Webinar on BCMA-Targeted Therapies in Relapsed Refractory Multiple Myeloma

Learn about ways to maximize efficacy, moderate adverse events, and improve the patient experience when using novel BCMA-targeted therapies in RRMM. This webinar/symposium was originally delivered on November 30, 2021, when BLENREP monotherapy was approved in the US and EU for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US and EU. The GSK compound discussed in this presentation is investigational. The information in this presentation is not intended to imply that clinical safety or efficacy of the compound has been established to the satisfaction of any regulatory authority or that it will receive regulatory approval.